PE20070796A1 - Metodo de produccion proteica utilizando compuestos anti-senescencia - Google Patents

Metodo de produccion proteica utilizando compuestos anti-senescencia

Info

Publication number
PE20070796A1
PE20070796A1 PE2006001284A PE2006001284A PE20070796A1 PE 20070796 A1 PE20070796 A1 PE 20070796A1 PE 2006001284 A PE2006001284 A PE 2006001284A PE 2006001284 A PE2006001284 A PE 2006001284A PE 20070796 A1 PE20070796 A1 PE 20070796A1
Authority
PE
Peru
Prior art keywords
carnosine
combinserin
antibody
cellular
under conditions
Prior art date
Application number
PE2006001284A
Other languages
English (en)
Inventor
Yen-Tung Luan
Wenge Wang
Denis Drapeua
Judy Chou
Paul Thoday
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37873105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070796(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20070796A1 publication Critical patent/PE20070796A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A UN METODO PARA PRODUCIR PROTEINAS TAL COMO UN ANTICUERPO, SIENDO SELECCIONADO EL ANTICUERPO ANTI-GDF-8 DEL GRUPO FORMADO POR MYO29, MYO28, MYO22 Y SUS COMBINACIONES, QUE COMPRENDE EN: A) CULTIVAR CELULAS DE MAMIFEROS QUE CONTIENE EL GEN QUE CODIFICA LA PROTEINA DE INTERES, DONDE DICHO GEN ES EXPRESADO BAJO CONDICIONES DE CULTIVO CELULAR EN UN MEDIO QUE ADEMAS COMPRENDE UN COMPUESTO ANTI-SENESCENCIA TAL COMO CARNOSINA, ACETIL-CARNOSINA, HOMO-CARNOSINA, ANSERINA Y E-CARNITINA O COMBINACIONES DONDE DICHO COMPUESTO ESTA PRESENTE EN UNA CONCENTRACION ENTRE 5 mM Y 100 mM, Y DONDE EL CULTIVO CELULAR ES PROVISTO ADEMAS CON COMPONENETES SUPLEMENTARIOS FORMADOS POR HORMONAS Y/O OTROS FACTORES DE CRECIMIENTO, IONES PARTICULARES, TAMPONES, ENTRE OTROS; B)MANTENER EL CULTIVO BAJO CONDICIONES Y DURANTE UN TIEMPO SUFICIENTE PARA PERMITIR LA EXPRESION PROTEICA. LAS CELULAS CULTIVADAS EN DICHO MEDIO DE CULTIVO CELULAR EXHIBEN MAYOR VIABILIDAD Y PRODUCTIVIDAD Y ADEMAS DICHOS CULTIVOS PRESENTAN NIVELES REDUCIDOS DE AGREGADOS DE ELEVADO PESO MOLECULAR
PE2006001284A 2005-10-24 2006-10-23 Metodo de produccion proteica utilizando compuestos anti-senescencia PE20070796A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72957305P 2005-10-24 2005-10-24

Publications (1)

Publication Number Publication Date
PE20070796A1 true PE20070796A1 (es) 2007-08-15

Family

ID=37873105

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001284A PE20070796A1 (es) 2005-10-24 2006-10-23 Metodo de produccion proteica utilizando compuestos anti-senescencia

Country Status (24)

Country Link
US (1) US20070110743A1 (es)
EP (1) EP1941026B1 (es)
JP (2) JP2009512459A (es)
KR (1) KR101402634B1 (es)
CN (1) CN101297027B (es)
AR (1) AR058140A1 (es)
AU (1) AU2006306433B2 (es)
BR (1) BRPI0617744A2 (es)
CA (1) CA2627003C (es)
CR (1) CR9897A (es)
DK (1) DK1941026T3 (es)
EC (1) ECSP088395A (es)
ES (1) ES2485374T3 (es)
HK (1) HK1120552A1 (es)
IL (1) IL190550A (es)
NI (1) NI200800111A (es)
NO (1) NO20081622L (es)
PE (1) PE20070796A1 (es)
PL (1) PL1941026T3 (es)
PT (1) PT1941026E (es)
RU (1) RU2491347C2 (es)
SI (1) SI1941026T1 (es)
TW (1) TW200736397A (es)
WO (1) WO2007050498A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2668212T3 (es) 2006-07-13 2018-05-17 Wyeth Llc Producción de factor de coagulación IX con patrón de glucosilación mejorado
SG10201510384UA (en) 2006-09-13 2016-01-28 Abbvie Inc Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
WO2010048192A2 (en) 2008-10-20 2010-04-29 Abbott Laboratories Viral inactivation during purification of antibodies
MX2011004200A (es) * 2008-10-20 2011-05-24 Abbott Lab Aislamento y purificacion de anticuerpos usando la cromatografia de afinidad de proteina a.
EP2464739B1 (en) 2009-08-14 2016-01-13 Basf Se Methods in cell cultures, and related inventions, employing certain additives
EP2601287B1 (en) 2010-08-05 2015-01-07 Amgen Inc. Dipeptides to enhance yield and viability from cell cultures
KR20130101034A (ko) * 2010-08-31 2013-09-12 프리슬랜드 브랜즈 비브이 진핵 세포를 위한 배양 배지
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
TW201247874A (en) * 2011-05-25 2012-12-01 United Biomedical Inc Method for producing the activity of bone activating protein
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
EP2970382B1 (en) * 2013-03-13 2019-09-25 Anteis SA Peptides for skin rejuvenation and methods of using the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
CA2903596C (en) * 2013-03-15 2023-10-03 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057910A1 (en) 2013-10-16 2015-04-23 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN104398398A (zh) * 2014-10-27 2015-03-11 陈少威 一种细胞量子动力素(平衡剂)及其使用方法
MA40864A (fr) * 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
US11401509B2 (en) 2015-11-09 2022-08-02 Bristol-Myers Squibb Company Methods of minimizing glycoprotein agregation in CHO cell production
US20190048070A1 (en) * 2016-01-06 2019-02-14 Oncobiologics, Inc. Reduction of high molecular weight species, acidic charge species and fragments in a monoclonal antibody composition
US11285210B2 (en) 2016-02-03 2022-03-29 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
CN111201434A (zh) * 2017-10-16 2020-05-26 瑞泽恩制药公司 用于控制细胞培养物中的过程变量的原位拉曼光谱系统和方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1132471A3 (de) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0571390B1 (en) * 1990-11-23 2000-03-08 Peptech Limited The delay, prevention and/or reversal of cell senescence
LU91067I2 (fr) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
RU2245365C2 (ru) * 1994-01-03 2005-01-27 Генентек Инк. Тромбопоэтин
US5830761A (en) * 1995-06-07 1998-11-03 Genetics Institute, Inc. Medium and methods for culturing mammalian cho cells
RU2134120C1 (ru) * 1995-06-26 1999-08-10 Безруков Михаил Васильевич Средство для стабилизации пептидной связи в белковом препарате
DK0859841T3 (da) * 1995-08-18 2002-09-09 Morphosys Ag Protein/(poly)peptidbiblioteker
JP4306813B2 (ja) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
CA2273194C (en) * 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
WO2002085932A2 (en) * 2001-04-24 2002-10-31 Innogenetics N.V. Constructs and methods for expression of recombinant hcv envelope proteins
JP4541157B2 (ja) * 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
DK1678208T3 (da) * 2003-10-27 2013-07-08 Wyeth Llc Fjernelse af aggregater med høj molekylvægt under anvendelse af hydroxyapatitchromatografi
WO2005064013A1 (en) * 2003-12-23 2005-07-14 Bart Janssen The use of carnosine metabolism-associated genes to determine genetic predisposition/susceptibility to diabetic nephropathy
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US7426440B2 (en) * 2004-09-24 2008-09-16 Nutritional Bioscience Ltd. Repair and protection factor scoring method for bioactive agents

Also Published As

Publication number Publication date
PL1941026T3 (pl) 2014-12-31
NO20081622L (no) 2008-06-18
JP2009512459A (ja) 2009-03-26
RU2008113220A (ru) 2009-12-10
WO2007050498A2 (en) 2007-05-03
CA2627003A1 (en) 2007-05-03
CN101297027B (zh) 2013-04-03
EP1941026A2 (en) 2008-07-09
SI1941026T1 (sl) 2014-07-31
BRPI0617744A2 (pt) 2011-08-02
ES2485374T3 (es) 2014-08-13
NI200800111A (es) 2009-03-03
CA2627003C (en) 2018-08-28
AU2006306433B2 (en) 2013-04-18
JP5907928B2 (ja) 2016-04-26
WO2007050498A3 (en) 2007-07-12
PT1941026E (pt) 2014-07-31
DK1941026T3 (da) 2014-07-21
JP2013165728A (ja) 2013-08-29
KR20080063365A (ko) 2008-07-03
RU2491347C2 (ru) 2013-08-27
EP1941026B1 (en) 2014-06-04
KR101402634B1 (ko) 2014-06-03
AR058140A1 (es) 2008-01-23
IL190550A0 (en) 2008-11-03
US20070110743A1 (en) 2007-05-17
CN101297027A (zh) 2008-10-29
TW200736397A (en) 2007-10-01
HK1120552A1 (en) 2009-04-03
ECSP088395A (es) 2008-05-30
IL190550A (en) 2017-01-31
CR9897A (es) 2008-07-29
AU2006306433A1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
PE20070796A1 (es) Metodo de produccion proteica utilizando compuestos anti-senescencia
EA200801074A1 (ru) Способы получения искусственных гибридных семян
MX2021005809A (es) Composiciones a base de levadura para mejorar las propiedades de la rizósfera y la fitosanidad.
AR064512A1 (es) Plantas con rasgos relacionados con rendimiento aumentado y un metodo para desarrollar las mismas
DE602006018587D1 (de) Verfahren zur verbesserten isolierung rekombinant produzierter proteine
AR062193A1 (es) Plantas con caracteristicas mejoradas y un metodo para su desarrollo
CL2009000912A1 (es) Metodo para la produccion de bmp-2 que comprende; cultivar una celula huesped que comprende la molecula de adn que codifica bmp-2 en medio de cultivo en presencia de hierro, un compuesto polianionico y piridoxal; recuperar la proteina de interes donde la celula huesped se cultiva en bioreactor.
BR112016018103A2 (pt) ?polipeptídeo e seu uso, polinucleotídeo, composição, proteína de fusão, método para controlar uma população, método para inibir o crescimento, método para controlar a infestação, planta ou célula vegetal, construto?
AR066380A1 (es) Metodo para incrementar el rendimiento en plantas en condiciones de disponibilidad reducida de nutrientes y un metodo para desarrollarlas
ECSP077246A (es) Formulaciones Estabilizadoras
UA92157C2 (ru) Способ продуцирования гормона роста
MX2009012451A (es) Plantas con rasgos mejorados relacionados con el rendimiento y un metodo para producirlas.
MX2011011453A (es) Plantas que tienen mejores rasgos relacionados con el rendimiento y un metodo para producirlas.
AR070693A1 (es) Plantas que tienen rasgos aumentados relacionados con el rendimiento y un metodo para obtenerlas a partir de la expresion del polipeptido de nitrato 2 (nrt2)
EA201490709A1 (ru) Адъювантное соединение
EA201270440A1 (ru) Растения с улучшенными характеристиками урожайности и способ их получения
SG158025A1 (en) Growth medium c. histolyticum without ingredients of mamalian sources
ATE493500T1 (de) Pflanzen mit veränderten wachstumseigenschaften und verfahren zu deren herstellung
ATE542907T1 (de) Chimäre promotoren, befähigt zur vermittlung der genexpression in pflanzen durch pathogeninfektion und deren anwendungen
EA200800253A1 (ru) Бессывороточная культуральная среда для получения рекомбинантных гонадотропинов
AU2008220715A8 (en) Plants having enhanced yield-related traits and a method for making the same
EA202091349A1 (ru) Способы культивирования клеток
EA201290599A1 (ru) Фотобиореактор закрытого типа для культивирования фотосинтетических микроорганизмов
AR056153A1 (es) Preparacion de estirpes celulars progenitoras para vacunas, usando cultivos de suspension de plantas biotecnologicas
ATE482282T1 (de) Pflanzen mit verbesserten wachstumseigenschaften und verfahren zur herstellung davon

Legal Events

Date Code Title Description
FX Voluntary withdrawal